ABLi Therapeutics (“ABLi”), a biotechnology company developing therapeutics to address diseases that arise from activation of Abelson Tyrosine Kinases (c-Abl kinases), announces publication of the ...
Researchers at City St. George’s, University of London, have identified a new molecular signature that may explain why patients with aggressive HER2-positive breast cancer developed resistance to ...
Resistant cells demonstrated global decreases in DNA accessibility with localized opening at resistance-driving loci, indicating non-mutational epigenetic reprogramming rather than canonical oncogenic ...
Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for subcutaneous amivantamab and hyaluronidase-lpuj as ...
EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight ...
BACKGROUND: BCR-ABL tyrosine kinase inhibitors (TKIs) have been increasingly linked to pulmonary arterial hypertension (PAH) since 2009, although supporting evidence is limited. Our objective was to ...
Regulatory submission is based on positive results from the Phase 2 PROSPECT Study —– FDA sets PDUFA Date of December 18, 2026 —OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera ...
Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved a new, simplified monthly dosing schedule* for RYBREVANT FASPROtm (amivantamab and hyaluronidase-lpuj). When ...
Monthly dosing reduces treatment visits while maintaining established safety and efficacy1,2 Builds on RYBREVANT FASPRO FDA approval to deliver the simplest and fastest ...
You're probably the exception if you don't know someone who drinks Diet Coke religiously. For many a soda lover, it's a no-calorie alternative to their favorite beverage, and it provides a jolt of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results